A Long-term Follow-up Study of Patients Who Received VOR33
← catalyst calendarSponsored by Vor Biopharma (industry) · VOR — their whole pipeline →.
Phase
—
Status
Terminated
Study type
Observational
Enrollment
10actual
Sites
11
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Lack of Funding
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-04-15 | actual | When the study began enrolling |
| Primary completion | 2025-05-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-28 | actual | The whole study's end, after follow-up |
| First posted | 2022-04-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Leukemia, Myeloid, Acute
Intervention
- Genetic: VOR33
Primary outcome
what the primary-completion date above is the date OFLong term safety of VOR33 in patients who participated in a VOR33 study in terms of study product-related Adverse Events/Serious Adverse Events (AEs/SAEs).
measured Years 1-15
Permalink · VOR's whole pipeline · Catalyst calendar · Every registered study · What changed